Gastroenteropancreatic neuroendocrine tumours
Irvin M. Modlin(Yale University), Anders Sundin, Martyn Caplin(The Royal Free Hospital), Ramón Salazar(Institut Català d'Oncologia), Gregory Kaltsas(National and Kapodistrian University of Athens), Steven F. Moss(Brown University), Ola Nilsson(Karolinska University Hospital), Rajesh V. Thakker(Queen Mary University of London), Daniel C. Chung(Massachusetts General Hospital), Kjell Öberg(Uppsala University Hospital), Robert T. Jensen(National Institutes of Health), Eric P. Krenning(Cyclotron (Netherlands)), Gianfranco Delle Fave(CTO Andrea Alesini), Guido Rindi(Agostino Gemelli University Polyclinic), Philippe Ruszniewski(Inserm), Wouter W. de Herder(Erasmus University Rotterdam)
Cited by 1,754
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k